COVID-19 Human IgM IgG ELISA kit(Nucleocapsid Protein)

96T ¥150,000


​※ 正規代理店ページへ移動します




Measurement method:   Indirect ELISA

Measurement wavelength:   450 nm

Measurement sample:   Serum

Species reactivity:    Human

Storage temperature:   Store at 2-8 ° C

Expiration date:   This product is valid for 12 months after production.

Immobilized antigen: SARS-CoV-2 nucleocapsid protein (Full length, E. coli expression system)

Kit contents

1. SARS-CoV-2 nucleocapsid protein-immobilized plate

2. HRP-conjugated anti-human IgM antibody

3. HRP-conjugated anti-human IgG antibody

4. Wash buffer(10× PBST)

5. Bovine serum albumin (for diluent)

6. Diluent buffer (10× )

7. R-1: Chromogenic substrate (TMB)

8. R-2: Stop reagent (1 mol/L hydrochloric acid)

9. Microplate seal


10 μL×1

10 μL×1

100 mL×1


50 mL×1

22 mL×1

22 mL×1


Measurement principle

  1. The SARS-CoV-2 recombinant nucleocapsid protein on an immobilized plate is reacted with an antibody (hereinafter referred to as human IgM/IgG) in a sample that recognizes it.

  2. After the reaction, the sample is removed by washing.

  3. React with human IgM/IgG on immobilized plates with HRP (horseradish peroxidase)- conjugated anti-human IgM/IgG antibodies.

  4. Remove excess HRP-conjugated anti-human IgM/IgG antibodies by washing. Add a chromogenic substrate and measure the absorbance.

Significance of measurement

This kit is a research ELISA kit to detect human IgM and IgG antibodies that recognize the

nucleocapsid protein of SARS-CoV-2, the causative virus of Covid-19.
Virus detection can be broadly divided into two approaches: one is to detect the virus itself,

such as PCR method, and the other is to detect the immune response that develops during infection (IgG, IgM, IgA). In common infections, IgM is an antibody produced early in the infection and disappears with relief of symptoms. IgG begins to be produced later than IgM and continues to be produced for months after healing. This is known to reduce the symptoms of the next infection or to prevent the onset of the next infection.


  • Xin Xu et al.
    Seroprevalence of Immunoglobulin M and G Antibodies Against SARS-CoV-2 in China

     Nat Med. 2020 Jun 5. PubMed PMID: 32504052​​​

  • Wanbing Liu et al.
    Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies Against SARS-CoV-2

     J Clin Microbiol . 2020 May 26. PubMed PMID: 32229605​

  • Fatima Amanat et al.
    A Serological Assay to Detect SARS-CoV-2 Seroconversion in Humans
    Nat Med. 2020 May 12. PubMed PMID: 32511441

  • Nandini Sethuraman et al.
    Interpreting Diagnostic Tests for SARS-CoV-2
    JAMA. 2020;323(22):2249-2251. PubMed PMID: 32374370

  • Fei Xiang et al.
    Antibody Detection and Dynamic Characteristics in Patients With COVID-19
    Clin Infect Dis. 2020 Apr 19. PubMed PMID: 32306047

  • Sarah Ee Fang Yong et al.
    Connecting clusters of COVID-19: an epidemiological and serological investigation
    Lancet Infect Dis. 2020 Apr 21. PubMed PMID: 32330439

  • Juanjuan Zhao et al.
    Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019
    Cin Infect Dis. 2020 Mar 28. PubMed PMID: 3

  • Li Guo et al.
    Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
    Clin Infect Dis. 2020 Mar 21. PubMed PMID: 32198501


1.)Keiichi Hiramatsu, Standard Textbook of standard microbiology, 11th edition, Medical study (2012)

2.)Anu Haveri , “Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland,” January to February 2020 , Eurosurveillance.  Volume 25, Issue 11, 19, Mar 2020.

3.)Wanbing Liu, “Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2”, J Clin Microbiol. 2020 Mar 30.

4.)Li Guo, “Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)”, Clin Infect Dis. 2020 Mar 21.

5.)Juanjuan Zhao, “Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”, Clin Infect Dis. 2020 Mar 21.

​↓Click here for product inquiry↓

Cellspect Co., Ltd.


2-4-23 Kitaioka, Morioka, Iwate Prefecture

TEL : +81 19-681-6710 / FAX  : +81 19-903-0418



COVID-19 Related Products

TEL : +31 3-5825-3557


Berthold Japan Co., Ltd.

COVID-19 Related Interviews

TEL : +81 19-134-6616


Copyright ©2018 cellspect All Rights Reserved. Wix.comで作成したホームページです。